Similar articles

• Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?

  Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, Socratous F, Kaye DM, Schlaich MP, Hickie I, Lambert GW. Barton DA, et al. J Hypertens. 2007 Oct;25(10):2117-24. doi: 10.1097/HJH.0b013e32829baae7. J Hypertens. 2007. PMID: 17885556
• Autonomy of autonomic dysfunction in major depression.

  Koschke M, Boettger MK, Schulz S, Berger S, Terhaar J, Voss A, Yeragani VK, Bär KJ. Koschke M, et al. Psychosom Med. 2009 Oct;71(8):852-60. doi: 10.1097/PSY.0b013e3181b8bb7a. Epub 2009 Sep 24. Psychosom Med. 2009. PMID: 19779146 Clinical Trial.
• Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk.

  Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, Haikerwal D, Kaye DM, Hotchkin EJ, Lambert GW. Dawood T, et al. Hypertens Res. 2007 Apr;30(4):285-93. doi: 10.1291/hypres.30.285. Hypertens Res. 2007. PMID: 17541206 Clinical Trial.
• Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD).

  van Gestel AJ, Kohler M, Clarenbach CF. van Gestel AJ, et al. Discov Med. 2012 Dec;14(79):359-68. Discov Med. 2012. PMID: 23272688 Review.
• Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality.

  Von Ruden AE, Adson DE, Kotlyar M. Von Ruden AE, et al. J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):32-40. doi: 10.1177/1074248407308467. J Cardiovasc Pharmacol Ther. 2008. PMID: 18287588 Review.